

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



B2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 31/135	A1	(11) International Publication Number: WO 97/33572 (43) International Publication Date: 18 September 1997 (18.09.97)
--	----	---

(21) International Application Number: PCT/US97/04584

(22) International Filing Date: 13 March 1997 (13.03.97)

(30) Priority Data:  
60/013,520 15 March 1996 (15.03.96) US

(71) Applicant (for all designated States except US): SOMERSET  
PHARMACEUTICALS, INC. [US/US]; 5415 West Laurel  
Street, Tampa, FL 33607-1729 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BOBOTAS, George  
[US/US]; 1245 North Florida Avenue, Tarpon Springs, FL  
34689 (US).

(74) Agent: SANZO, Michael, A.; Vinson & Elkins, 1455 Pennsyl-  
vania Avenue, N.W., Washington, DC 20004-1008 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY,  
CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS,  
JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD,  
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,  
ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT,  
LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**

*With international search report.*

*Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.*

(54) Title: METHOD FOR PREVENTING AND TREATING PERIPHERAL NEUROPATHY BY ADMINISTERING SELEGILINE

(57) Abstract

The present invention is directed to methods for alleviating the symptoms associated with peripheral neuropathy. The neuropathy may be the result of a genetically inherited condition, systemic disease or exposure to a toxic agent. A reduction or elimination of symptoms is obtained by administering the drug selegiline. The invention is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with selegiline.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## Method for Preventing and Treating Peripheral Neuropathy By Administering Selegiline

---

### *Field of the Invention*

The present invention relates to a medical treatment for preventing or alleviating the symptoms associated with peripheral neuropathy caused by disease or exposure to a toxic agent, e.g., a chemotherapeutic cytotoxic agent. A reduction or elimination of symptoms is accomplished by administering the drug selegiline.

### *Background of the Invention*

Peripheral neuropathy is associated with a wide variety of causes, including genetically acquired conditions, systemic disease or exposure to toxic agents. It can manifest itself as a dysfunction of motor, sensory, sensorimotor or autonomic nerves.

Among the most important toxic agents causing peripheral neuropathy are therapeutic agents, particularly those used for the treatment of neoplastic disease. In certain cases, peripheral neuropathy is a major complication of cancer treatment and is the main factor limiting the dosage of chemotherapeutic that can be administered to a patient (Macdonald, *Neurologic Clinics* 9:955-967 (1991)). This is true for the commonly administered agents cisplatin, paclitaxel and vincristine (Broun, *et al.*, *Am. J. Clin. Oncol.* 16:18-21 (1993); Macdonald, *Neurologic Clinics* 9:955-967 (1991); Casey, *et al.*, *Brain* 96:69-86 (1973)). The identification of methods for preventing or alleviating dose-limiting peripheral neuropathologic side effects would allow higher, and more therapeutically effective doses of these chemotherapeutics to be administered to patients, i.e., the therapeutic efficacy of such chemotherapeutics is typically a function of dose and therefore, increasing dosage provides increased patient survival (Macdonald, *Neurologic Clinics* 9:955-967 (1991); Oxols, *Seminars in Oncology* 16, suppl. 6:22-30 (1989)).

Beyond the potential for increasing the effectiveness of cancer chemotherapy, the identification of new methods for treating peripheral neuropathy has obvious value in alleviating the suffering of patients with a wide variety of systemic diseases and genetic conditions. In many cases, progressive neuropathy in the peripheral nervous system can be debilitating or fatal.

Although selegiline has been used extensively as a treatment for Parkinson's disease, its effectiveness in the prevention or treatment of peripheral nerve dysfunction caused by

-2-

toxic agents has not been previously known. The present invention is directed to methods which rely upon this surprising and unexpected discovery to reduce or eliminate symptoms associated with peripheral nerve dysfunction.

### *Related Art*

5        Selegiline is a potent and selective irreversible inhibitor of monoamine oxidase B (MAO-B) and has been reported to have an action in protecting or rescuing neurons of the central nervous system. For example, in a rat optic nerve crush model, selegiline has been reported to increase the survival of retinal ganglion cells that are at risk of undergoing apoptosis (Buys, *et al.*, *Invest. Ophthalmol. Vis. Sci.* 35:1484 (1994)). Selegiline has also  
10        been shown to have a neuroprotective effect in a model of axotomy-induced cell death in spinal motor neurons of the rat (Iwasaki, *et al.*, *J. Neurol. Sci.* 125:11-13 (1994)) and to enhance neurite outgrowth in a cultured spinal cord neuron (Iwasaki, *et al.*, *Annals of Neurology* 36:282-283 (1994)). In addition, selegiline has been reported to increase the survival of CNS neurons after exposure to various chemical toxins such as MPP<sup>+</sup>, kainic  
15        acid, or DSP-4 (Gelowitz, *et al.*, *Soc. Neurosci. Abstr.* 20:246 (1994); Tatton, *et al.*, *J. Neurosci. Res.* 31:394-400 (1992); Yu, *et al.*, *J. Neurochem.* 63:1820-1828 (1994)).

20        With respect to peripheral nerves, selegiline has been reported to be capable of rescuing axotomized rat facial motor neurons (Salo, *et al.*, *J. Neurosci. Res.* 31:394-400 (1992)). A recently issued patent also suggests that it may be used in stimulating muscle reinnervation in traumatic and non-traumatic peripheral nerve damage (U.S. No. 5,444,095).

### *Summary of the Invention*

25        The present invention is based upon the discovery that selegiline can be used to prevent or alleviate the symptoms associated with peripheral neuropathy. In particular, the invention provides a method for protecting a patient from, or treating a patient for, peripheral neuropathy caused by a toxic agent by administering selegiline in an amount sufficient to reduce or eliminate one or more of the symptoms associated with the neuropathy. Typically, the patient will be a human and the toxic agent will be a chemotherapeutic agent, *e.g.*, an agent administered for the treatment of cancer. Although the method is effective for any toxic

-3-

chemotherapeutic agent causing dysfunction of peripheral nerves, it is most effective for those agents with particularly severe neuropathic side effects such as cisplatin, paclitaxel, vincristine and vinblastin

Any route of delivery may be used for administering the drug, but preferred routes avoid absorption of selegiline from the gastrointestinal tract. Thus, administration transdermally, buccally, or sublingually are among the preferred methods of delivery. The preferred non-oral dose of selegiline is between 0.01 mg/kg per day and 0.15 mg/kg per day, based upon the weight of the free amine. When the oral route of delivery is used, the preferred dosage range is between 0.15 mg/kg per day and 0.75 mg/kg per day based upon the weight of the free amine (typically between about 10 and 50 mg per day).

The present invention is also directed to a method for treating a patient for peripheral neuropathy caused by a genetically inherited condition or systemic disease by administering selegiline in an amount sufficient to reduce or eliminate one or more of the symptoms associated with the neuropathy. As in the case where peripheral neuropathy is due to exposure to a toxic agent, it is preferred that selegiline be administered by a route that avoids absorption of the drug from the gastrointestinal tract. Transdermal, buccal and sublingual routes of administration are among the routes preferred. Again, the dosage of selegiline for non-oral routes of administration should be between 0.01 mg/kg per day and 0.15 mg/kg per day and, when given orally, the preferred dosage range is between 0.15 mg/kg per day and 0.75 mg/kg per day.

The present invention is also directed to a method for treating a patient with cancer by: a) administering a chemotherapeutic agent known to have a toxic effect on peripheral nerves at a dose effective at slowing the progression of the patient's cancer; b) concurrently administering selegiline to the patient at a dose effective at preventing, reducing or eliminating the peripheral neuropathy associated with the chemotherapeutic agent; and c) increasing the individual or cumulative dosage of chemotherapeutic agent until peripheral neuropathy becomes unacceptably severe. Individual dosage refers to the amount of chemotherapeutic given at a single time, e.g. in a single infusion or injection, whereas cumulative dosage is the total amount of a chemotherapeutic administered over the full course of therapy. Thus, cumulative dosage may be increased by increasing individual dosages,

extending the period of therapy or both increasing individual dosages and extending the length of therapy.

The present invention provides the following:

5 In a method for maximizing the individual or cumulative dose of an anti-neoplastic agent used in the treatment of a patient suffering from a cancer that exhibits a dose-dependent response to said agent, the improvement that comprises the concurrent administration of a selegiline compound in an amount sufficient to permit the individual or cumulative dose of said agent to be maximized without unacceptably severe neurotoxic side effects.

10 As used herein "concurrent" administration of selegiline and chemotherapeutic means that the drugs are given sufficiently close in time so that their therapeutic effects overlap. The term "unacceptably severe" refers to side effects that the patient finds intolerable or which the patient's physician judges to reflect neuropathy that poses so serious a threat to the patient's health that the dosage of chemotherapeutic agent must be reduced or terminated. Typically, the patient will be a human. The preferred chemotherapeutic agents are cisplatin,  
15 paclitaxel, vincristine and vinblastine.

As with the methods discussed previously, selegiline may be administered by any route, but routes that avoid absorption across the gastrointestinal tract, e.g., transdermal, buccal and sublingual routes, are generally preferred. The non-oral dosage of selegiline administered in conjunction with chemotherapeutic agent should, preferably, be between 0.01  
20 mg/kg per day and 0.15 mg/kg per day based upon the weight of the free amine. In general, patients administered selegiline orally should receive a dose of between 0.15 mg/kg per day and 0.75 mg/kg per day.

### *Detailed Description of the Invention*

25 In the following description, reference will be made to various methodologies well known to those skilled in the art of medicine and pharmacology. Such methodologies are described in standard reference works setting forth the general principles of these disciplines.


-5-

### A. Definitions

**Peripheral neuropathy:** As used herein, the term "peripheral neuropathy" refers to abnormal function or pathological changes in nerves located outside of the brain or spinal column. The nerves may be sensory, motor, sensorimotor or autonomic and dysfunction may manifest itself in any of the various symptoms discussed herein.

**Toxic agent:** For the purposes of the present invention, the term "toxic agent" is defined as any substance that, through its chemical action, impairs the normal function of one or more components of the peripheral nervous system. The definition includes agents that are airborne, ingested as a contaminant of food or drugs, or taken deliberately as part of a therapeutic regime.

**Selegiline:** Selegiline, also known as R-(-)-N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane, L-(-)-deprenyl, or R-(-)-deprenyl, has the following structural formula:



Unless otherwise specified, the term "selegiline," as used herein includes both the free base and pharmacologically acceptable salts of selegiline.

### B. Symptoms of Peripheral Neuropathy

The present invention is directed to the prevention or treatment of peripheral neuropathy using selegiline. The neuropathy may be genetically acquired, developed as the result of systemic illness, or due to the exposure of a patient to a toxic agent. The treatment objective is to prevent, reduce or eliminate the symptoms associated with peripheral nerve dysfunction.

-6-

Symptoms vary widely depending upon the cause of the peripheral nerve damage and the particular types of nerves affected. Dysfunction of peripheral sensory neurons typically manifests itself as a loss of sensation in the limbs or elsewhere. For example, there may be numbness in the fingers, toes or elsewhere. Clinically, a physician may evaluate such loss by testing the ability of a patient to sense pain, vibration, or temperature or by using nerve conductance studies.

Dysfunction in peripheral motor neurons typically manifests itself as a clumsiness in performing physical tasks or as muscular weakness. For example, a patient may experience difficulty in buttoning a shirt or combing their hair. Muscular weakness may cause patients to become exhausted after relatively minor exertion and, in some cases, may create a difficulty in standing or walking. Clinically, a physician may diagnosis dysfunction in motor neurons using electrophysiological tests or by direct evaluation of patient strength or dexterity. Peripheral motor neuron dysfunction may also be diagnosed on the basis of an attenuation or absence of a neuromuscular reflex, *e.g.*, as an absence of the ankle jerk reflex.

Dysfunction of peripheral autonomic nerves may lead a patient to experience constipation or cardiac irregularities or toxicities. It is often seen clinically as an attenuation of the postural hypotensive reflex.

### C. Diseases and Toxic Agents Causing Peripheral Neuropathy

The particular systemic disease, hereditary condition or toxic agent responsible for peripheral neuropathy is not critical to the invention. Thus, selegiline is effective for neuropathies associated with systemic diseases such as: uremia; childhood cholestatic liver disease; chronic respiratory insufficiency; alcoholic polyneuropathy; multiple organ failure; sepsis; hypo-albuminemia; eosinophilia-myalgia syndrome; hepatitis; porphyria; hypoglycemia; vitamin deficiency; chronic liver disease; primary biliary cirrhosis; hyperlipidemia; leprosy; Lyme disease; herpes zoster; Guillain-Barre syndrome; chronic inflammatory demyelinating polyradiculoneuropathy; sensory perineuritis; acquired immunodeficiency syndrome (AIDS) - associated neuropathy; Sjogren's syndrome; primary vasculitis (such as polyarteritis nodosa); allergic granulomatous angiitis; hypersensitivity angiitis; Wegener's granulomatosis; rheumatoid arthritis; systemic lupus erythematosus; mixed connective tissue



disease; scleroderma; sarcoidosis; vasculitis; systemic vasculitides; acute tunnel syndrome; pandysautonomia; primary, secondary, localized or familial systemic amyloidosis; hypothyroidism; chronic obstructive pulmonary disease; acromegaly; malabsorption (sprue, celiac disease); carcinomas (sensory, sensorimotor, late and demyelinating); lymphoma  
5 (including Hodgkin's), polycythemia vera; multiple myeloma (lytic type, osteosclerotic, or solitary plasmacytoma); benign monoclonal gammopathy; macroglobulinemia; cryoglobulinemia; tropical myeloneuropathies; herpes simplex infection; cytomegalovirus infection; and diabetes.

Genetically acquired neuropathies suitable for treatment by selegiline include, without  
10 limitation: peroneal muscular atrophy (Charcot-Marie-Tooth Disease) hereditary amyloid neuropathies, hereditary sensory neuropathy (type I and type II), porphyric neuropathy, hereditary liability to pressure palsy, Fabry's Disease, adrenomyeloneuropathy, Riley-Day Syndrome, Dejerine-Sottas neuropathy (hereditary motor-sensory neuropathy-III), Refsum's  
15 disease, ataxia-telangiectasia, hereditary tyrosinemia, anaphalipoproteinemia, abetalipoproteinemia, giant axonal neuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy, and Friedrich's ataxia.

A very large number of toxic agents have been described that cause peripheral neuropathy amenable to treatment by the present invention. The list includes, but is not limited to, acetazolamide, acrylamide, adriamycin, alcohol, almitrine, amiodarone,  
20 amphotericin, arsenic, aurothioglucose, carbamates, carbon disulfide, carboplatin, chloramphenicol, chloroquine, cholestyramine, cisplatin, clioquinol, colestipol, colchicine, colistin, cycloserine, cytarabine, dapsone, dideoxycytidine, dideoxyinosine, dideoxythymidine, disulfiram, doxorubicin, ethambutol, ethionamide, glutethimide, gold, hexacarbons, hormonal contraceptives, hexamethylmelamine, hydralazine,  
25 hydroxychloroquine, imipramine, indomethacin, inorganic lead, inorganic mercury, isoniazid, lithium, methylmercury, metformin, methylbromide, methylhydrazine, metronidazole, misonidazole, nitrofurantoin, nitrogen mustard, nitrous oxide, organophosphates, ospolot, penicillin, perhexiline, perhexiline maleate, phenytoin, platinum, polychlorinated biphenyls, primidone, procarbazine, pyridoxine, sodium cyanate,  
30 streptomycin, sulphonamides, suramin, tamoxifen, paclitaxel, thalidomide, thallium,

-8-

triamterene, trimethyltin, L-tryptophan, vacor, vindesine, megadoses of vitamin A, megadoses of vitamin D, and zimeldine.

Although the particular disease or toxic agent causing peripheral nerve damage is not critical, the present invention will be particularly valuable in the treatment of peripheral neuropathy resulting from the administration of chemotherapeutic agents to cancer patients. Among the chemotherapeutics known to cause peripheral neuropathy are vincristine, vinblastine, cisplatin, paclitaxel, procarbazine, dideoxyinosine, cytarabine, alpha interferon, and 5-fluorouracil (see Macdonald, *Neurologic Clinics* 9: 955-967 (1991)).

**D. Method of Preventing or Treating Peripheral Neuropathy  
by the Administration of Selegiline**

*Dosage*

The total daily dosage of selegiline administered to a patient, typically a human patient, should be at least the amount required to minimize, reduce or eliminate one or more of the symptoms associated with peripheral neuropathy, typically one of the symptoms discussed above. Ordinarily, the attending physician will administer an initial daily non-oral dose of at least about 0.01 mg per kg of body weight, calculated on the basis of the free secondary amine, with progressively higher doses being employed depending upon the response to therapy. The final daily dose will be between about 0.05 mg/kg of body weight and about 0.15 mg/kg of body weight (all such doses again being calculated on the basis of the free secondary amine).

These are simply guidelines since the actual dose must be carefully selected and titrated by the attending physician based upon clinical conditions. The optimal daily dose will be determined by methods known in the art and will be influenced by factors such as the age of the patient, the condition or disease associated with the peripheral neuropathy, the severity of both the neuropathy and the disease, the condition of the patient to whom treatment is being given, the desired degree of therapeutic response, and the concomitant therapies being administered. Dosages may be provided in either a single or multiple dosage regimen

*Dosage Forms and Route of Administration*

Any route of administration and dosage form is compatible with the present invention and there are numerous references that provide guidance in this respect. For example, U.S. patent 4,812,481 discloses the use of concomitant selegiline-amantadine therapy in which selegiline is used with amantadine in oral, peroral, internal, pulmonary, rectal, nasal, vaginal, lingual, intravenous, intraarterial, intracardial, intramuscular, intraperitoneal, intracutaneous, and subcutaneous formulations. U.S. patent 5,192,550 describes a dosage form for selegiline comprising an outer wall with one or more pores, in which the wall is impermeable to selegiline but permeable to external fluids. This dosage form may have applicability for oral, sublingual, or buccal administration. Similarly, U.S. patent 5,387,615 discloses a variety of selegiline compositions, including tablets, pills, capsules, powders, aerosols, suppositories, skin patches, parenterals, and oral liquids, include oil aqueous suspensions, solutions, and emulsions. Further disclosed therein are selegiline-containing sustained release (long acting) formulations and devices.

Although any route of administration is compatible with the present invention, those that avoid the absorption of selegiline from the gastrointestinal tract are generally preferred. Thus, preferred routes include parenteral, transdermal, buccal, intraocular and sublingual administration. Parenteral compositions containing selegiline may be prepared according to conventional techniques. For example, sterile isotonic saline may be used in preparations designed for intramuscular, intravenous, intrathecal or intraarterial delivery. Sterile isotonic solutions can also be employed for intraocular administration.

Transdermal dosage unit forms can be prepared utilizing a variety of techniques that have been described in the art. For example, in U.S. patent numbers 4,861,800; 4,868,218; 5,128,145; 5,190,763; and 5,242,950; and in the foreign patent documents EP-A 404807; EP-A 509761; and EP-A 593807. A monolithic patch structure can be utilized in which selegiline is directly incorporated into the adhesive and this mixture is cast on to a backing sheet. Alternatively, selegiline as an acid addition salt can be incorporated into a multi layer patch which effects a conversion of the salt to selegiline-free base, as described for example in EP-A 593807. One can also employ a device using a lyotropic liquid crystalline composition in which, for example, 5-15% of selegiline is combined with a mixture of liquid

-10-

and sold polyethylene glycols, a polymer, and a non-ionic surfactant, optionally with the addition of propylene glycol and an emulsifying agent. For further details on the preparation of such transdermal formulations, reference can be made to EP-A 5509761.

Buccal and sublingual dosage forms of selegiline may be prepared utilizing techniques described in, for example, U.S. patent 5,192,550; 5,221,536; 5,266,332; 5,057,321; 5,446,070; 4,826,875; 5,304,379; or 5,354,885.

### *Form of Selegiline*

The present invention is not limited to a particular form of selegiline and the drug may be used either as a free base or as a pharmaceutically acceptable acid addition salt. In the latter case, the hydrochloride salt is generally preferred. However, other salts useful in the invention include those derived from organic and inorganic acids such as, without limitation, hydrobromic acid, phosphoric acid, sulfuric acid, methane sulfonic acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, aconitic acid, salicylic acid, thalic acid, embonic acid, enanthic acid, and the like.

### *Manner of Treatment*

The methods disclosed herein may be used for both human and non-human subjects. With regard to the latter, the methods are particularly, but not exclusively, directed to domesticated mammals such as canine and feline species.

Treatment by the administration of selegiline should be continued until the symptoms associated with peripheral neuropathy subside. The drug may be either administered at regular intervals (*e.g.*, twice a day) or delivered in an essentially continuous manner, *e.g.*, via a transdermal patch. Patients should be regularly evaluated by physicians, *e.g.* once a week, to determine whether there has been an improvement in symptoms and whether the dosage of selegiline needs to be adjusted. Since delayed progressive neuropathy has been demonstrated after the cessation of cisplatin therapy (*see e.g.* Grunberg *et al.*, *Cancer Chemother. Pharmacol.* 25:62-64 (1989)), it is preferred that administration of selegiline be continued for a period (*e.g.* from about 1 - 12 months) after the end of chemotherapy.

E. Method of Treating Cancer Patients Using a Combination of Selegiline and Chemotherapeutic

The present invention is also directed to a method for treating cancer patients using a combination of chemotherapeutic agent and selegiline. Except as noted below, the same considerations discussed in the sections above apply equally to the situation in which selegiline is used as part of a therapeutic regime for such patients.

*Chemotherapeutic Agents*

Selegiline may be used in combination with any chemotherapeutic agent that causes peripheral neuropathy as a side effect. However, treatment is especially preferred for chemotherapeutic agents that are so toxic that their dosage is limited by the peripheral neuropathy which they cause. Included in this group are paclitaxel, cisplatin, vincristine and vinblastine. By preventing or reducing the peripheral neuropathy associated with these agents, selegiline allows higher individual doses to be administered to patients, thereby increasing the overall efficacy of the therapy. In addition, the administration of selegiline allows patients to receive a higher cumulative dose of chemotherapeutic agent. Increased cumulative dose may result from higher doses of agent being administered at each therapeutic cycle, an increase in the number of cycles, or a combination of higher doses and more cycles.

The most preferred chemotherapeutic agents for use in the present invention are cisplatin and paclitaxel, both of which have severe toxicity for peripheral nerves limiting their upper dosages (see Macdonald, *Neurologic Clinics* 9: 955-967 (1991)). Although dose intensity of these agents is an important factor in achieving optimal therapeutic results, doses substantially above about 100-120 mg/m<sup>2</sup> for cisplatin (Ozols, *Seminars in Oncology* 16: 22-30 (1989)) and about 175 mg/m<sup>2</sup> - 225 mg/m<sup>2</sup> for paclitaxel (Gianni, *et al.*, *J. Nat'l Cancer Inst.* 87:1169-75 (1995)), typically cannot be given.

The symptoms associated with peripheral neuropathy caused by the administration of cisplatin include sensory polyneuropathy with paresthesias, vibratory and proprioceptive loss, loss of pin and temperature sensation, and reduced deep tendon reflexes (see Macdonald, *Neurologic Clinics* 9:955-967 (1991); Ozols, *Seminars in Oncology* 16, suppl. 6:22-30 (1989)). Symptoms associated with other agents such as vincristine and paclitaxel include

-12-

loss of deep tendon reflex response at the ankle which may progress to complete areflexia, distal symmetric sensory loss, motor weakness, foot drop, muscle atrophy, constipation, ileus, urinary retention, impotence, and postural hypotension (*Id.*; Casey, *et al.*, *Brain* 96: 69-86 (1973)). For the purposes of the present invention, the severity of these symptoms is considered to be unacceptable when either a patient judges them to be intolerable or the patient's physician judges them to pose so serious a threat to the patient's health that the dosage of chemotherapeutic agent must be reduced or discontinued.

#### *Dosage Forms and Routes of Administration*

The particular route of administration that is most preferred will be determined by clinical considerations and may include any of the routes of delivery or dosage forms discussed above. Routes of administration which avoid gastrointestinal absorption will often be preferred in that these are believed to reduce the concentration of undesirable metabolic products of selegiline generated *in vivo*. Thus, preferred routes will typically include transdermal, parenteral, sublingual and buccal administration.

#### *Dosage and Manner of Treatment*

In some instances, patients administered selegiline according to the invention, will already have been on chemotherapy at the time that selegiline treatment is initiated. As a result, an upper limit on dosage of chemotherapeutic may already have been established, beyond which the patient experiences unacceptably severe peripheral neuropathy. In these cases, administration of the chemotherapeutic agent should be maintained and treatment with selegiline initiated at a non-oral dose of between 0.01 mg/kg of body weight per day and 0.15 mg/kg per day. The exact time at which chemotherapeutic and selegiline are given relative to one another is not critical to the invention provided that their therapeutic effects overlap. For example, it is not essential that chemotherapeutic and selegiline be administered in a single dosage form or within an hour or two of one another.

In instances in which a patient is taking multiple drugs or in which there is some reason to believe that they may be unusually sensitive to selegiline, it may be desirable to start with a low initial dose (*e.g.*, 0.01 mg/kg) in order to ensure that the patient is able to

tolerate the medication. Once this is established, the dosage may be adjusted upward with the preferred final dosage for non-oral routes of administration being approximately in the range of 0.05 to 0.15 mg/kg per day. When given orally, patients should typically receive a total daily dose of between 0.15 mg/kg per day and 0.75 mg/kg per day divided into several doses.

5 For example, a patient may receive a dose of 5 mg orally, twice a day.

The effect of selegiline on the symptoms of peripheral neuropathy should be evaluated by the patient over a period of time and by the patient's physician on a regular basis (*e.g.*, once a week). If the results reveal that symptoms have not subsided, the daily dosage of non-oral selegiline may be increased up to a limit of about 0.15 mg/kg. Once a concentration of  
10 selegiline is established which is effective at reducing symptoms, the dosage of chemotherapeutic is increased until a new upper limit is established, *i.e.* until a dosage is established which cannot be exceeded without causing unacceptable side effects. The administration of selegiline should be continued for a period of time after the administration of chemotherapeutic has ceased in order to prevent delayed progressive neuropathy. For  
15 example, the patient may continue to receive selegiline for a month or more after the end of chemotherapy.

The same basic procedure described above can be used for patients beginning chemotherapy. In these cases, both the dosage of chemotherapeutic agent and selegiline will have to be established. The preferred procedure is to begin by pretreating patients with  
20 selegiline before the administration of chemotherapeutic is begun. For example, a patient may be given 10 mg of selegiline per day for a period of one week before treatment with chemotherapeutic is initiated. The dosages of both chemotherapeutic and selegiline are then optimized as described above. Again, selegiline administration should be continued after the administration of chemotherapeutic has stopped.

25 The examples below are for illustrative purposes only and are not intended to limit the scope of the invention.

### Examples

#### Example 1: Treatment of Peripheral Neuropathy Caused by Vincristine

A patient with endometrial carcinoma is given an intravenous bolus injection of vincristine at a dose of  $1.4 \text{ mg/m}^2$  weekly. The toxic effects of vincristine cause sensory loss  
5 in the fingers and toes, a loss of the ankle jerk reflex, weakness and postural hypotension. The patient is administered 5 mg of selegiline hydrochloride orally twice a day, once with breakfast and once at lunch. During this time, therapy with vincristine is continued and evaluations of both tumor response and toxic side effects are carried out by a physician on a weekly basis. After continued therapy, symptoms associated with peripheral neuropathy  
10 subside. At this point, the dosage of vincristine is increased to  $1.8 \text{ mg/m}^2$  and the process is continued. If symptoms of peripheral neuropathy do not return at the end of another cycle of chemotherapy, dosage is increased again until an upper limit is reached. After the final dose of vincristine is given, selegiline administration is maintained for a period of one month.

#### Example 2: Administration of Selegiline in Combination With Cisplatin

15 A patient with ovarian cancer is given weekly injections of cisplatin at a dosage of  $120 \text{ mg/m}^2$ . Concurrently, the patient is given an oral dose of 5 mg of selegiline hydrochloride twice a day. At the end of one week, the patient is evaluated for signs of peripheral neuropathy. If no symptoms appear, the dose of selegiline is maintained and the dosage of cisplatin is increased to  $140 \text{ mg/m}^2$  per week. This process is continued until an upper limit  
20 of cisplatin is identified. The effect of the therapy on tumor progression is evaluated to determine the efficacy of the treatment.

#### Example 3: Treatment of Peripheral Neuropathy Caused by Paclitaxel

A patient with breast cancer is administered selegiline orally (10 mg per day) for a period of one week. At the end of this time, treatment with paclitaxel is begun by infusing  
25 the drug intravenously at a dose of  $175 \text{ mg/m}^2$  over a period of 3 hours. Treatment is repeated every 3 weeks for a total of ten cycles, with the dosage of paclitaxel being increased by  $25 \text{ mg/m}^2$  at each cycle. During this time, treatment with selegiline is continued and evaluations of both tumor response and toxic side effects are carried out by a physician on



-15-

a weekly basis. Dosage of paclitaxel continues to be increased until side effects become unacceptably severe. Administration of selegiline is continued for one month after treatment with paclitaxel ends.

**Example 4: Alternative Therapeutic Regime Using Paclitaxel and Selegiline**

5       A patient with breast cancer is administered selegiline via a transdermal patch at a dose of about 0.10 mg/kg per day for a period of one week. At the end of this time, treatment with paclitaxel is begun by infusing the drug intravenously at a dose of 175 mg/m<sup>2</sup> over a period of 3 hours. Paclitaxel infusion is repeated every 3 weeks. During this time, treatment with selegiline is continued and evaluations of both tumor response and toxic side effects are  
10       carried out by a physician on a weekly basis. If peripheral neuropathy becomes unacceptably severe the dosage of selegiline is increased to about 0.15 mg/kg per day. If unacceptable side effects persist, the dosage of paclitaxel is reduced to 125 mg/m<sup>2</sup>. Treatment cycles are continued for a period extending as long as a beneficial effect on tumor progression is obtained or until unacceptable side effects can no longer be eliminated. Administration of  
15       selegiline is continued for one month after treatment with paclitaxel ends.

---

All references cited herein are fully incorporated by reference. Having now fully described the invention, it will be understood by one of skill in the art that the invention may be performed within a wide and equivalent range of conditions, parameters and the like, without effecting the spirit or scope of the invention or any embodiment thereof.

*What is Claimed is:*

1. A method of preventing or treating peripheral neuropathy caused by a toxic agent in a patient in need of such prevention or treatment, said method comprising:  
administering selegiline to said patient in an amount sufficient to prevent, reduce or eliminate one or more of the symptoms associated with said peripheral neuropathy.
2. The method of claim 1, wherein said patient is a human.
3. The method of claim 1, wherein said agent is a chemotherapeutic agent.
4. The method of claim 3, wherein said chemotherapeutic agent is administered for the treatment of cancer.
5. The method of claim 4, wherein said agent is selected from the group consisting of cisplatin, paclitaxel, vincristine and vinblastin.
6. The method of claim 1, wherein said selegiline is administered by a route that avoids absorption of selegiline from the gastrointestinal tract.
7. The method of claim 6, wherein said selegiline is administered transdermally, buccally or sublingually.
8. The method of claim 6, wherein said selegiline is administered at a dose of between 0.01 mg/kg per day and 0.15 mg/kg per day based upon the weight of the free amine.
9. A method of treating a patient for peripheral neuropathy caused by a genetically inherited condition or systemic disease, said method comprising:  
administering selegiline to said patient in an amount sufficient to reduce or eliminate one or more of the symptoms associated with said peripheral neuropathy.

-17-

10. The method of claim 9, wherein said patient is a human.
11. The method of claim 9, wherein said selegiline is administered by a route that avoids absorption of selegiline from the gastrointestinal tract
12. The method of claim 11, wherein said selegiline is administered transdermally, buccally or sublingually.
13. The method of claim 11, wherein said selegiline is administered at a dose of between 0.01 mg/kg per day and 0.15 mg/kg per day.
14. In a method for maximizing either the individual or cumulative dose of an anti-neoplastic agent used in the treatment of a patient suffering from a cancer that exhibits a dose-dependent response to said agent, the improvement that comprises the concurrent administration of a selegiline compound in an amount sufficient to permit the individual or cumulative dose of said agent to be maximized without unacceptably severe neurotoxic side effects.
15. A method for treating a patient with cancer which comprises:
  - a) administering to said patient a chemotherapeutic agent known to have a toxic effect on peripheral nerves, wherein said chemotherapeutic agent is administered at a dose effective at slowing the progression of said cancer;
  - b) concurrently administering selegiline to said patient at a dose effective at reducing or eliminating the peripheral neuropathy associated with said chemotherapeutic agent;
  - c) increasing the individual or cumulative dosage of chemotherapeutic agent until the peripheral neuropathy becomes unacceptably severe.
16. The method of claim 15, wherein said patient is a human.

-18-

17. The method of claim 15, wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, paclitaxel, vincristine and vinblastin.
18. The method of claim 15, wherein said selegiline is administered by a route that avoids absorption of selegiline from the gastrointestinal tract.
19. The method of claim 18, wherein said selegiline is administered transdermally, buccally or sublingually.
20. The method of claim 18, wherein said selegiline is administered at a dose of between 0.01 mg/kg per day and 0.15 mg/kg per day.

# INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 97/04584

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 92 17169 A (UNIVERSITY OF TORONTO) 15 October 1992 ---	
A	US 5 444 095 A (TATTON ET AL.) 22 August 1995 cited in the application ---	
A	US 4 868 218 A (BUYSKE) 19 September 1989 ---	
A	BIOL. PSYCHIATRY, vol. 33, no. 10, 1993, pages 700-706, XP002035062 D.C. GOFF ET AL.: "a placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia." -----	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

11 July 1997

Date of mailing of the international search report

24. 07. 97

Name and mailing address of the ISA  
European Patent Office, P.B. 5218 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Klaver, T

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/04584

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 1-20  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6A(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern al Application No

PCT/US 97/04584

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9217169 A	15-10-92	AU 1450592 A	02-11-92
		EP 0578687 A	19-01-94
		JP 6506204 T	14-07-94
		US 5444095 A	22-08-95
-----			
US 5444095 A	22-08-95	AU 1450592 A	02-11-92
		WO 9217169 A	15-10-92
		EP 0578687 A	19-01-94
		JP 6506204 T	14-07-94
-----			
US 4868218 A	19-09-89	CA 1329132 A	03-05-94
		US 4861800 A	29-08-89
		US RE34579 E	05-04-94
		AU 628340 B	17-09-92
		AU 3502289 A	22-11-90
		EP 0406488 A	09-01-91
		CN 1048320 A	09-01-91
-----			